H. pylori Eradication in an 80-Year-Old Woman with Gastritis
For this 80-year-old woman with H. pylori gastritis, I recommend bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) for 14 days as first-line treatment, or alternatively vonoprazan-amoxicillin dual therapy if available, as both achieve >90% eradication rates in elderly patients with favorable safety profiles 1, 2.
First-Line Treatment Options
The 2021 AGA guidelines specifically acknowledge that elderly patients are a "vulnerable population" requiring careful consideration of treatment burden 1. For treatment-naive patients, you have two excellent options:
Preferred Regimen: Bismuth Quadruple Therapy
- Bismuth subsalicylate ~300mg four times daily
- Metronidazole 500mg three to four times daily (total 1.5-2g/day)
- Tetracycline 500mg four times daily
- PPI (standard dose) twice daily
- Duration: 14 days 1, 3
This regimen is particularly advantageous because:
- Achieves >90% eradication even with metronidazole-resistant strains 1, 3
- Avoids clarithromycin and fluoroquinolones (where resistance is rising)
- Well-tolerated in elderly patients with adverse event rates of 13-19% 2, 4
Alternative: Vonoprazan-Amoxicillin Dual Therapy (if available)
- Vonoprazan 20mg twice daily
- Amoxicillin 1000mg three times daily
- Duration: 14 days
Recent 2026 data specifically in elderly patients (≥60 years) showed this achieved 96.3% eradication with only 13.8% adverse events 2. This is particularly attractive for an 80-year-old as it's simpler (fewer pills) and highly effective 5.
Critical Considerations for Elderly Patients
Dosing Adjustments
- Amoxicillin: Use at least 2g daily divided three to four times daily to maintain adequate trough levels 1
- PPI: Use high-dose twice daily (e.g., omeprazole 40mg BID, pantoprazole 80mg BID) as inadequate acid suppression is a major cause of failure 1
- Metronidazole: Ensure adequate dosing at 1.5-2g daily in divided doses 1
Pre-Treatment Assessment
Before prescribing, you must:
- Review antibiotic history: If she's had prior macrolides (clarithromycin, azithromycin), avoid clarithromycin-based regimens. If prior fluoroquinolones, avoid levofloxacin 1
- Check for penicillin allergy: If labeled as allergic but no anaphylaxis history, consider allergy testing to potentially use amoxicillin-based regimens 1
- Assess adherence barriers: Complex regimens may not be comprehended; explain dosing clearly and address polypharmacy concerns 1, 4
- Review comorbidities: Adjust only if severe renal insufficiency (CrCl <30) for certain antibiotics 4
Safety Profile in the Elderly
The evidence is reassuring: eradication therapy in elderly patients causes predominantly mild, short-term adverse events with compliance rates of 87-100% 6, 4. The most common side effects are gastrointestinal (nausea, diarrhea, metallic taste) but rarely lead to discontinuation 4, 7.
Important: Treatment does NOT increase risk of Clostridioides difficile infection in elderly patients 4.
Alternative First-Line Options (if bismuth unavailable)
Concomitant Non-Bismuth Quadruple Therapy
- PPI twice daily
- Amoxicillin 1000mg twice daily
- Clarithromycin 500mg twice daily
- Metronidazole 500mg twice daily
- Duration: 14 days 3
Use this only if local clarithromycin resistance is <15% and she has no prior macrolide exposure 1, 3.
What NOT to Use First-Line
Avoid standard triple therapy (PPI + clarithromycin + amoxicillin): The 2025 meta-analysis showed 7-day standard triple therapy achieved only 81% eradication in elderly patients—unacceptable 6. Even 14-day regimens are restricted due to rising clarithromycin resistance (>30% in many regions) 8.
Avoid levofloxacin-based regimens first-line: Reserve for rescue therapy due to high fluoroquinolone resistance rates 1, 3.
If First-Line Therapy Fails
After confirming adherence:
Second-line: Switch to levofloxacin triple therapy (PPI + amoxicillin 1000mg BID + levofloxacin 500mg daily × 14 days) OR rifabutin triple therapy (PPI + amoxicillin + rifabutin 150mg BID × 10-14 days) 1
After two failures: Obtain H. pylori susceptibility testing to guide subsequent therapy 1
Shared decision-making: After multiple failures in an 80-year-old, carefully weigh benefits of continued eradication attempts against treatment burden, especially if she has limited life expectancy or terminal illness 1
Benefits of Eradication in This Patient
Despite her age, eradication offers substantial benefits:
- Prevents peptic ulcer recurrence (58-78% of elderly ulcers are H. pylori-related) 9
- Reduces gastric cancer risk (though benefit diminishes with advanced age and existing atrophy) 6, 4
- Improves chronic gastritis and may prevent progression of intestinal metaplasia 7
- Cost-effective: Reduces healthcare costs from recurrent disease 9
Common Pitfalls to Avoid
- Underdosing PPIs: Use twice-daily dosing, not once daily 1
- Insufficient duration: Always use 14 days for first-line therapy in elderly patients 1, 3
- Not checking prior antibiotic exposure: This predicts resistance patterns 1
- Assuming age is a contraindication: Age alone should not preclude treatment unless terminal illness present 4, 5
- Using 7-day regimens: These are inadequate in elderly populations 6